OverviewSuggest Edit

Immunomedics is a clinical-stage biopharmaceutical company that is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its technologies allow to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

TypePublic
Founded1982
HQMorris Plains, US
Websiteimmunomedics.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2017)138
Job Openings68
Revenue (FY, 2018)$2.2 M(-30%)
Share Price (Jun 2019)$12.7 (-1%)

Key People/Management at Immunomedics

David M. Goldenberg

David M. Goldenberg

Founder
Usama Malik

Usama Malik

Chief Business Officer
Show more

Immunomedics Office Locations

Immunomedics has an office in Morris Plains
Morris Plains, US (HQ)
300 The American Rd
Show all (1)

Immunomedics Financials and Metrics

Immunomedics Revenue

Embed Graph
View revenue for all periods
Immunomedics's revenue was reported to be $2.16 m in FY, 2018
USD

Revenue (FY, 2018)

2.2m

Gross profit (FY, 2018)

1.5m

Gross profit margin (FY, 2018), %

71.5%

Net income (FY, 2018)

(273.9m)

EBIT (FY, 2018)

141.0m

Market capitalization (10-Jun-2019)

2.4b

Closing stock price (10-Jun-2019)

12.7

Cash (31-Dec-2018)

492.9m
Immunomedics's current market capitalization is $2.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

5.0m9.0m5.7m3.2m3.1m2.2m

Cost of goods sold

392.7k338.6k264.9k1.2m482.7k613.6k

Gross profit

4.6m8.7m5.4m2.1m2.6m1.5m

Gross profit Margin, %

92%96%95%64%84%72%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.2m1.2m1.1m1.0m1.2m730.9k671.1k899.1k741.8k384.2k1.3m690.5k1.3m1.8m

Cost of goods sold

103.1k90.3k76.3k69.0k72.8k58.3k64.5k337.7k255.1k46.8k135.6k70.2k566.8k613.6k

Gross profit

1.1m1.1m995.7k933.8k1.1m672.6k606.6k561.4k486.7k337.4k1.2m620.3k721.0k1.2m

Gross profit Margin, %

91%92%93%93%94%92%90%62%66%88%90%90%56%65%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

41.3m7.0m13.5m13.2m43.4m492.9m

Accounts Receivable

303.1k857.1k236.8k

Inventories

1.0m779.0k584.4k350.5k580.0k

Current Assets

45.2m44.7m103.5m53.0m157.3m504.5m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

6.8m5.0m5.4m2.8m16.1m11.8m13.7m11.2m8.5m5.0m21.9m43.0m61.0m306.7m

Accounts Receivable

77.4k300.6k101.4k185.4k85.6k26.8k270.8k236.8k111.2k

Inventories

886.7k823.2k732.4k676.8k624.4k539.2k490.7k170.7k329.4k737.9k685.6k527.7k43.3k

Current Assets

30.2m23.7m35.5m24.5m109.6m89.0m78.8m64.4m36.1m48.8m48.5m147.4m148.6m369.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(11.5m)(35.5m)(48.1m)(59.1m)(153.3m)(273.9m)

Depreciation and Amortization

1.0m569.4k578.1k737.7k923.3k1.3m

Inventories

(618.0k)204.4k328.1k256.4k(196.0k)

Accounts Payable

966.7k2.3m4.9m3.1m15.8m(1.5m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(14.1m)(9.5m)(12.4m)(11.5m)(11.8m)(15.4m)(29.2m)(43.2m)(16.2m)(40.7m)(59.3m)(118.8m)(121.3m)(156.8m)

Depreciation and Amortization

314.4k424.1k140.8k336.1k504.8k459.4k212.5k627.7k940.3k

Inventories

823.2k732.4k676.8k624.4k539.2k490.7k170.7k329.4k685.6k

Accounts Payable

4.5m9.3m9.0m8.8m12.0m14.9m13.5m14.1m19.6m(9.5m)
USDY, 2018

Revenue/Employee

15.6k

Financial Leverage

2 x
Show all financial metrics

Immunomedics Online and Social Media Presence

Embed Graph

Immunomedics News and Updates

Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

MORRIS PLAINS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its TROPHY-U-01 late-breaking abstract on interim results of sacituz…

Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan

The Largest Single-Asset License Agreement for Greater China To Date Provides Everest Medicines the Right to Develop and Commercialize Sacituzumab Govitecan for All Cancer Indications in Greater China, South Korea, and Certain ASEAN Countries

Immunomedics Announces Departure of Chief Medical Officer

MORRIS PLAINS, N.J., April 29, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Rob Iannone, M.D., has decided to leave the Company to pursue a care…

Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes

Preparation for Resubmission of BLA for Sacituzumab Govitecan Continuing

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

Publication Highlights Safety and Efficacy Profile of Sacituzumab Govitecan Addressing High Unmet Need in Metastatic Triple-Negative Breast Cancer Publication Highlights Safety and Efficacy Profile of Sacituzumab Govitecan Addressing High Unmet Need in Metastatic Triple-Negative Breast Cancer

IMMU CLASS ACTION: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important Deadline in Class Action Seeking to Recover Investor Losses - IMMU

NEW YORK, Feb. 12, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunomedics, Inc. from August 23, 2018 through December 20, 2018, inclusive (the "Class Period") of the important February 25, 2019 lead plaintiff deadline...
Show more

Immunomedics Blogs

Immunomedics to Host Investor Event and Webcast on September 28, 2019 during ESMO Congress

The post Immunomedics to Host Investor Event and Webcast on September 28, 2019 during ESMO Congress appeared first on Immunomedics.

Immunomedics Announces Oral Presentation of Sacituzumab-Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

The post Immunomedics Announces Oral Presentation of Sacituzumab-Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress appeared first on Immunomedics.

Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update

The post Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update appeared first on Immunomedics.

Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019

The post Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019 appeared first on Immunomedics.

Immunomedics to Participate in Upcoming Healthcare Conferences

The post Immunomedics to Participate in Upcoming Healthcare Conferences appeared first on Immunomedics.

Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update

The post Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update appeared first on Immunomedics.
Show more

Immunomedics Frequently Asked Questions

  • When was Immunomedics founded?

    Immunomedics was founded in 1982.

  • Who are Immunomedics key executives?

    Immunomedics's key executives are David M. Goldenberg and Usama Malik.

  • How many employees does Immunomedics have?

    Immunomedics has 138 employees.

  • What is Immunomedics revenue?

    Latest Immunomedics annual revenue is $2.2 m.

  • What is Immunomedics revenue per employee?

    Latest Immunomedics revenue per employee is $15.6 k.

  • Who are Immunomedics competitors?

    Competitors of Immunomedics include Blue Water Vaccines, Nuvo Pharmaceuticals and Sosei Heptares.

  • Where is Immunomedics headquarters?

    Immunomedics headquarters is located at 300 The American Rd, Morris Plains.

  • Where are Immunomedics offices?

    Immunomedics has an office in Morris Plains.

  • How many offices does Immunomedics have?

    Immunomedics has 1 office.